IONS ▼ -6.3% - Ionis Pharmaceuticals, Inc. $IONS Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) Ionis’ partner Novartis announced topline Phase 3 results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease, highlighting immediate market attention to the program and potential downstream milestones. The public disclosure of favorable topline data on an Lp(a)-targeting therapy underscores a clear upside path for Ionis via collaboration milestones, potential regulatory discussions, and future commercialization opportunities tied to the Lp(a) program. The after-hours release signals confirmatory interest in the anchor program and its leverage for broader portfolio momentum. Ionis Pharmaceuticals fell 6.3% today following Novartis's announcement of Phase 3 topline results for pelacarsen, an Lp(a)-targeting therapy developed through the companies' partnership. While the headline describes the data as favorable and highlights potential milestone payments and commercialization opportunities for Ionis, the stock's decline suggests investors may have focused on specific efficacy or safety metrics from the trial results that fell short of expectations, or concerns about the competitive landscape in the Lp(a) space. 04-SEP-2026 04:45 PM ET